Literature DB >> 12539169

Von Hippel-Lindau disease.

Toshiaki Sano1, Hidehisa Horiguchi.   

Abstract

Von Hippel-Lindau (VHL) disease is an uncommon, autosomal dominant hereditary multitumor syndrome caused by germline alterations of the VHL gene, which has been cloned recently and identified as a tumor suppressor gene. The major lesions in VHL disease include hemangioblastomas in the central nervous system and retina, clear cell renal cell carcinomas, pheochromocytomas, pancreatic tumors, epididymal cystadenomas, endolymphatic sac tumors, carcinoid tumors, and multiple cysts of the kidney, pancreas, and epididymis. Compared with sporadic ones, the tumors in VHL disease develop at an earlier age and often multifocally. Histologic features of VHL tumors are characterized by their high degree of vascularization and the presence of a clear cell component. Hypervascularization is induced by overexpression of vascular endothelial growth factor (VEGF), and because the principal function of VHL protein is the negative regulation of hypoxia-inducible mRNAs including VEGF mRNA, inactivation of VHL gene plays critical roles in angiogenesis of the VHL tumors. In addition, since VHL protein is also required for the down-regulation of transcription activity of certain genes for the cell growth and cell cycle, inactivation of VHL gene may contribute to tumorigenesis of the VHL tumors. A significant difference in the frequency of types of VHL gene mutation has been noted among the affected families, known as the genotype-phenotype correlations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12539169     DOI: 10.1002/jemt.10253

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  6 in total

1.  VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.

Authors:  Tiffany N Seagroves; Danielle L Peacock; Debbie Liao; Luciana P Schwab; Robin Krueger; Charles R Handorf; Volker H Haase; Randall S Johnson
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

2.  VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study.

Authors:  Rachel K Pettman; Amy Crowley; Christie Riddell; Mark D Ludman
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Normalization of systemic arterial hypertension following removal of posterior fossa hemangioblastoma: a case report.

Authors:  Hooshang Saberi; Ali Tayebi Meybodi; Mehdi Zeinalizadeh
Journal:  Cases J       Date:  2009-04-29

4.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

5.  Carcinoid tumor of the common bile duct: a rare complication of von Hippel-Lindau syndrome.

Authors:  Otmane Nafidi; Bich-N Nguyen; André Roy
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

6.  A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.

Authors:  Su Jin Heo; Choong-Kun Lee; Kyu Yeon Hahn; Gyuri Kim; Hyuk Hur; Sung Hoon Choi; Kyung Seok Han; Arthur Cho; Minkyu Jung
Journal:  Cancer Res Treat       Date:  2015-02-17       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.